Carboplatin
Carboplatin is a second-generation platinum-based antineoplastic agent widely used in veterinary oncology. It is primarily utilized for the treatment of various carcinomas and sarcomas, most notably as an adjunctive therapy for **canine osteosarcoma** following amputation. **Clinical Pearls & Advantages:** * **Feline Safety:** Unlike its predecessor cisplatin (which causes fatal pulmonary edema in cats—often remembered by the mnemonic *"cisplatin splats cats"*), carboplatin is relatively safe and routinely used in feline patients. * **Reduced Toxicity:** Carboplatin is generally considered the "kinder, gentler" platinum agent. It exhibits significantly less nephrotoxicity and emetogenic (vomiting) potential compared to cisplatin, eliminating the need for aggressive pre- and post-treatment IV fluid diuresis. * **Versatility:** Beyond systemic IV administration, it has shown promise in intracavitary (pleural effusion), intra-arterial, and intralesional (equine sarcoids, feline nasal planum carcinomas) applications.
กลไกการออกฤทธิ์: Carboplatin acts as a **bifunctional alkylating agent**. * **Cellular Entry & Activation:** Once inside the cell, the drug undergoes aquation (water molecules replace the cyclobutanedicarboxylate leaving group), forming highly reactive, positively charged platinum complexes. * **DNA Crosslinking:** These active complexes bind covalently to nucleophilic sites on DNA (primarily the N7 position of guanine and adenine). * **Inhibition:** This binding creates **intra-strand and inter-strand crosslinks** in the DNA double helix, physically obstructing DNA polymerases and RNA polymerases. * **Apoptosis:** The resulting DNA damage inhibits DNA replication, RNA transcription, and protein synthesis, ultimately triggering apoptosis (programmed cell death). > **Note:** Carboplatin is **cell-cycle nonspecific**, meaning it can damage cells during any phase of the cell cycle, though cells are most vulnerable during the G1 and S phases.
ขนาดยาตามชนิดสัตว์
- Antineoplastic · 300-350 mg/m2 · IV · every 3 weeks · Dosage may need adjustment in patients with reduced renal function.
- Neoplastic diseases (All uses) · 300 mg/m2 · IV · q3-4wk · As determined by oncology protocol · Injected into the side port of a freely running i.v. infusion of 0.9% NaCl over a 10-15 min period.
- Neoplastic diseases (Intrapleural/intraperitoneal) · 225-300 mg/m2 · Intrapleural/Intraperitoneal · As directed by specialist · As determined by oncology protocol · Diluted in 0.9% NaCl or 5% dextrose water over a 5-10 min period. Consult a veterinary oncology specialist before administering via this route.
- Adenocarcinoma · Intralesional use may be considered · Intralesional
- Antineoplastic · 180-260 mg/m2 · IV · every 3 weeks · Has also been administered intratumorally for nasal planum carcinomas.
- Neoplastic diseases (All uses) · 200 mg/m2 · IV · q3-4wk · As determined by oncology protocol · Injected into the side port of a freely running i.v. infusion of 0.9% NaCl over a 10-15 min period. Monitor for delayed/unpredictable side effects.
- Neoplastic diseases (Intrapleural/intraperitoneal) · 200-240 mg/m2 · Intrapleural/Intraperitoneal · As directed by specialist · As determined by oncology protocol · Diluted in 0.9% NaCl or 5% dextrose water over a 5-10 min period. Consult a veterinary oncology specialist before administering via this route.
วิธีการให้ยา
ข้อห้ามใช้
- History of hypersensitivity to carboplatin or other platinum agents
- Severe bone marrow depression
- Pregnancy (fetotoxic and embryotoxic - Category D)
อาการไม่พึงประสงค์
- Bone marrow suppression (neutropenia, thrombocytopenia)
- Anorexia
- Vomiting (typically 2-4 days post-dose)
- Hepatotoxicity (elevated bilirubin and liver enzymes)
- Nephrotoxicity (less frequent than cisplatin)
- Neuropathies (rare)
- Ototoxicity (rare)
- Anaphylactoid reactions (rare)
- Hyperuricemia
อันตรกิริยาระหว่างยา
- Aminoglycosides · Potential for increased risk of nephrotoxicity or ototoxicity. · major
- Cisplatin · Patients previously treated with cisplatin have an increased risk of developing neurotoxicity or ototoxicity after receiving carboplatin.
- Myelosuppressive drugs · The leukopenic or thrombocytopenic effects secondary to carboplatin may be enhanced.
- Radiation therapy · Potential for increased hematologic toxicity.
- Vaccines · Live or killed virus vaccines administered after therapy may have reduced efficacy. Carboplatin may also potentiate live virus vaccine replication and increase adverse effects.
- Nephrotoxic agents (e.g., NSAIDs, Amphotericin B) · Increased risk of cumulative nephrotoxicity. · major
- Vaccines (live) · May adversely affect the safety and efficacy of vaccinations due to immunosuppression. · major
- Radiotherapy · Potential to act as a radiosensitizer for patients receiving concomitant radiotherapy. · moderate
การติดตาม
- CBC (Complete Blood Count) to monitor nadir
- Serum electrolytes
- Uric acid
- Baseline renal and hepatic function tests
การได้รับยาเกินขนาด
An overdose of carboplatin is expected to cause severe, aggravated effects associated with the drug's primary toxicities: **bone marrow suppression, nephrotoxicity, and hepatotoxicity**. * **Monitoring:** Closely monitor for neurotoxicity, ototoxicity, hepatotoxicity, and nephrotoxicity. * **Treatment:** Therapy is primarily supportive as no specific antidote is available. Plasmapheresis or hemodialysis could potentially be of benefit in rapidly removing the drug from systemic circulation.
ข้อมูลอ้างอิงยาของ VetSheet มีไว้สำหรับสัตวแพทย์ผู้มีใบอนุญาตเพื่อช่วยในการตัดสินใจทางคลินิก ไม่ใช่สิ่งทดแทนการวินิจฉัยของผู้เชี่ยวชาญหรือฉลากล่าสุดของผู้ผลิต